CUE Cue Biopharma Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: CUE

Price (delayed)

$2.13

Market cap

$103.61M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.11

Enterprise value

$66.95M

Cue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body to transform the ...

Highlights
The gross profit is up by 44% since the previous quarter
CUE's revenue is up by 44% since the previous quarter
Cue Biopharma's quick ratio has shrunk by 55% YoY and by 10% QoQ
The company's equity fell by 44% YoY and by 13% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.cuebiopharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of CUE
Market
Shares outstanding
48.64M
Market cap
$103.61M
Enterprise value
$66.95M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.59
Price to sales (P/S)
17.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.19
Earnings
Revenue
$5.49M
EBIT
-$49.49M
EBITDA
-$46.05M
Free cash flow
-$39.96M
Per share
EPS
-$1.11
Free cash flow per share
-$0.87
Book value per share
$0.82
Revenue per share
$0.12
TBVPS
$1.34
Balance sheet
Total assets
$61.53M
Total liabilities
$24.45M
Debt
$14.7M
Equity
$37.09M
Working capital
$34.37M
Liquidity
Debt to equity
0.4
Current ratio
3.01
Quick ratio
3.11
Net debt/EBITDA
0.8
Margins
EBITDA margin
-838.8%
Gross margin
100%
Net margin
-924.1%
Operating margin
-947%
Efficiency
Return on assets
-71.1%
Return on equity
-112.3%
Return on invested capital
-308.4%
Return on capital employed
-111.3%
Return on sales
-901.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CUE stock price

How has the Cue Biopharma stock price performed over time
Intraday
13.3%
1 week
56.62%
1 month
20.34%
1 year
-52.98%
YTD
-19.32%
QTD
12.7%

Financial performance

How have Cue Biopharma's revenue and profit performed over time
Revenue
$5.49M
Gross profit
$5.49M
Operating income
-$51.99M
Net income
-$50.73M
Gross margin
100%
Net margin
-924.1%
CUE's net margin has surged by 78% year-on-year and by 32% since the previous quarter
Cue Biopharma's operating margin has soared by 78% YoY and by 32% from the previous quarter
The gross profit is up by 44% since the previous quarter
CUE's revenue is up by 44% since the previous quarter

Growth

What is Cue Biopharma's growth rate over time

Valuation

What is Cue Biopharma stock price valuation
P/E
N/A
P/B
2.59
P/S
17.75
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.19
The EPS is up by 26% YoY and by 8% QoQ
The P/B is 46% below the 5-year quarterly average of 4.8 and 14% below the last 4 quarters average of 3.0
The company's equity fell by 44% YoY and by 13% QoQ
The price to sales (P/S) is 86% lower than the last 4 quarters average of 127.6 and 79% lower than the 5-year quarterly average of 85.6
CUE's revenue is up by 44% since the previous quarter

Efficiency

How efficient is Cue Biopharma business performance
The ROIC has shrunk by 124% YoY and by 53% QoQ
The ROS has soared by 79% YoY and by 32% QoQ
Cue Biopharma's return on equity has decreased by 28% YoY and by 13% QoQ
The ROA has contracted by 15% YoY and by 8% from the previous quarter

Dividends

What is CUE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CUE.

Financial health

How did Cue Biopharma financials performed over time
The total assets is 152% greater than the total liabilities
The current ratio has dropped by 55% year-on-year and by 10% since the previous quarter
Cue Biopharma's quick ratio has shrunk by 55% YoY and by 10% QoQ
CUE's debt is 60% smaller than its equity
The company's equity fell by 44% YoY and by 13% QoQ
CUE's debt to equity is up by 38% YoY and by 5% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.